Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

Leukemia Research

Volumn 39, Issue 9, 2015, Pages 950-956

  Badar, Talha ^a   Kantarjian, Hagop M ^a   Ravandi, Farhad ^a   Jabbour, Elias ^a   Borthakur, Gautam ^a   Cortes, Jorge E ^a   Pemmaraju, Naveen ^a   Pierce, Sherry R ^a   Newberry, Kate J ^a   Daver, Naval ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Accelerated phase; AML; Decitabine; Myelofibrosis; Myeloproliferative neoplasm

Indexed keywords

ANAGRELIDE; ANTIANEMIC AGENT; CYTARABINE; DECITABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; IMATINIB; LENALIDOMIDE; POMALIDOMIDE; PREDNISONE; RUXOLITINIB; THALIDOMIDE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM PLUS; FEMALE; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; MALE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SEPSIS; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLAST CRISIS; LEUKEMIA, MYELOID, ACCELERATED PHASE; MORTALITY; PATHOLOGY; PRIMARY MYELOFIBROSIS; PROSPECTIVE STUDY; REMISSION; SURVIVAL ANALYSIS;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLAST CRISIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84940961594     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.06.001     Document Type: Article

References (38)

1. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2013, 88(2):141-150.
2. Mesa R.A., et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105(3):973-977.
3. Gangat N., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 2011, 29(4):392-397.
4. Tefferi A., et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J. Clin. Oncol. 2009, 27(27):4563-4569.
5. Tefferi A., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108(4):1158-1164.
6. Mesa R.A., et al. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 2008, 22(8):1636-1638.
7. Mesa R.A., et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007, 21(9):1964-1970.
8. Abgrall J.F., et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006, 91(8):1027-1032.
9. Harrison C., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 2012, 366(9):787-798.
10. Verstovsek S., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 2012, 366(9):799-807.
11. Verstovsek S., et al. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica 2015, 100(4):478-488.
12. Cervantes F., Mesa R., Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007, 13(6):377-383.
13. Passamonti F., et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003, 88(1):13-18.
14. Tam C.S., et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008, 112(5):1628-1637.
15. Passamonti F., et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005, 104(5):1032-1036.
16. Vannucchi A.M., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27(9):1861-1869.
17. Wang J.C., et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br. J. Haematol. 2002, 116(3):582-586.
18. Martyre M.C. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr. Hematol. Rep. 2003, 2(3):257-263.
19. + cells in myelofibrosis with myeloid metaplasia. Blood 2001, 98(12):3249-3255.
20. + cells by treatment with chromatin-modifying agents. Cancer Res. 2009, 69(19):7612-7618.
21. + cells from patients with idiopathic myelofibrosis. Cancer Res. 2007, 67(13):6417-6424.
22. Nischal S., et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res. 2013, 73(3):1076-1085.
23. Plimack E.R., Kantarjian H.M., Issa J.P. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk. Lymphoma 2007, 48(8):1472-1481.
24. Issa J.P., Kantarjian H.M. Targeting DNA methylation. Clin. Cancer Res. 2009, 15(12):3938-3946.
25. Kantarjian H., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109(1):52-57.
26. Silverman L.R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002, 20(10):2429-2440.
27. Mascarenhas J., et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk. Res. 2010, 34(9):1246-1249.
28. Thepot S., et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010, 116(19):3735-3742.
29. Quintas-Cardama A., et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008, 22(5):965-970.
30. Vardiman J.W., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
31. Mascarenhas J., et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk. Res. 2012, 36(12):1500-1504.
32. Tefferi A., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013, 122(8):1395-1398.
33. Cheson B.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(2):419-425.
34. Verstovsek S., et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013, 98(12):1865-1871.
35. Eghtedar A., et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012, 119(20):4614-4618.
36. Tabarroki A., et al. Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leuk. Lymphoma 2014, 1-3.
37. Mascarenhas J., et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br. J. Haematol. 2013, 161(1):68-75.
38. Ballen K.K., et al. Outcome of transplantation for myelofibrosis. Biol. Blood Marrow Transplant. 2010, 16(3):358-367.